Imagine if the GLP1's did cause permanent weight loss. The headlines would say "Would you really want to take a drug that irreversibly alters your brain chemistry and metabolism!?" Also, what an insane bar - that the drugs should continue working after they're discontinued.

Zeer lezenswaardige special van FD Nieuws over kosten geneesmiddelen in NL . Spoiler: Die zijn laag en het valt dus allemaal erg mee, i.t.t. het bekende anti-farma narratief. specials.fd.nl/hoe-nederland-… Twee plaatjes:

I’ve given lots of 101 talks on the IRA… we’re past that now. This podcast with Duane Schulthess is the better version of the talk I’ve given to biotech audiences interested in how to treat the global root of the problem. Good for morning commute.

Aissam Dam, 11, was the first person to get gene therapy in the U.S. for congenital deafness. The treatment was a success, introducing a child who had known nothing of sound to a new world. “There’s no sound I don’t like,” he said. nyti.ms/47LmrPo

1. A hope-inspiring study on nirsevimab for #RSV control in Eurosurveillance today. From Luxembourg, which aimed to give nirsevimab to all babies born in 2023, plus kids <2 yo at high risk of serious illness. They managed to give it to 84% of eligible babies. And look.... 🧵

In today’s Health Affairs Forefront, jcohen & I argue that methods for valuing drug therapies need updating. tinyurl.com/4f3tkd9w CEVR Brian Reid UW School of Pharmacy ICER No Patient Left Behind NPC The Center for Innovation and Value Research Scott Gottlieb, MD 🇺🇸 Duke-Margolis

New MMWR: Early data show that nirsevimab — a preventive antibody for babies — was 90% effective in preventing babies from being hospitalized with RSV. To protect babies during #RSV season, nirsevimab is recommended October‒March. Learn more bit.ly/mm7309a4

Cystic fibrosis once guaranteed an early death—but a medical breakthrough has given many patients a chance to live decades longer than expected. What do they do now? Sarah Zhang reports: theatlantic.com/magazine/archi…

The world is relying on the United States to get value-based drug pricing right. trib.al/nG0v2B6

Important Friday The New York Times Reed Abelson Rebecca Robbins story on how vertically-integrated #PBMs pocket market savings at expense of sick customers. They "charge employers and CMSGov multiple times the wholesale Rx price, keeping most for themselves." nytimes.com/2024/06/21/bus…

Pharmacy benefit managers act as middlemen overseeing prescriptions for millions of Americans to reduce drug costs. A New York Times investigation found they charge steep prices for patients, employers and the government. Our reporter explains how. nyti.ms/3RESDih

Are you or a friend concerned about vaccines? Where there’s smoke, might there be fire, right? RA Capital's infectious disease team created a detailed Q&A document on nearly all the worries someone might have about vaccines.

Uiteraard.